Vivo Capital VIII, LLC - Dec 15, 2023 Form 4 Insider Report for IMPEL PHARMACEUTICALS INC (IMPL)

Role
10%+ Owner
Signature
Vivo Capital VIII, LLC, By: /s/ Frank Kung, Managing Member
Stock symbol
IMPL
Transactions as of
Dec 15, 2023
Transactions value $
-$74,131
Form type
4
Date filed
12/19/2023, 06:00 PM
Previous filing
Nov 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMPL Common Stock Sale -$25.5K -87.9K -3.47% $0.29 2.45M Dec 15, 2023 By: Vivo Capital Fund VIII, L.P. F1, F3
transaction IMPL Common Stock Sale -$3.5K -12.1K -3.45% $0.29 338K Dec 15, 2023 By: Vivo Capital Surplus Fund VIII, L.P. F2, F3
transaction IMPL Common Stock Sale -$23K -209K -8.54% $0.11* 2.24M Dec 18, 2023 By: Vivo Capital Fund VIII, L.P. F1, F4
transaction IMPL Common Stock Sale -$3.16K -28.7K -8.5% $0.11* 309K Dec 18, 2023 By: Vivo Capital Surplus Fund VIII, L.P. F2, F4
transaction IMPL Common Stock Sale -$16.7K -209K -9.32% $0.08* 2.03M Dec 19, 2023 By: Vivo Capital Fund VIII, L.P. F1, F5
transaction IMPL Common Stock Sale -$2.29K -28.6K -9.27% $0.08* 280K Dec 19, 2023 By: Vivo Capital Surplus Fund VIII, L.P. F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Vivo Capital VIII, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2 The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F3 The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.44 to $0.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4 The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.30 to $0.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
F5 The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.10 to $0.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.